ABSTRACT
Lysobacter enzymogenes is a Gram-negative, environmentally ubiquitous bacterium that produces a secondary metabolite, called heat-stable antifungal factor (HSAF), as an antifungal factor against plant and animal fungal pathogens. 4-Hydroxybenzoic acid (4-HBA) is a newly identified diffusible factor that regulates HSAF synthesis via L. enzymogenes LysR (LysRLe), an LysR-type transcription factor (TF). Here, to identify additional TFs within the 4-HBA regulatory pathway that control HSAF production, we reanalyzed the LenB2-based transcriptomic data, in which LenB2 is the enzyme responsible for 4-HBA production. This survey led to identification of three TFs (Le4806, Le4969, and Le3904). Of them, LarR (Le4806), a member of the MarR family proteins, was identified as a new TF that participated in the 4-HBA-dependent regulation of HSAF production. Our data show the following: (i) that LarR is a downstream component of the 4-HBA regulatory pathway controlling the HSAF level, while LysRLe is the receptor of 4-HBA; (ii) that 4-HBA and LysRLe have opposite regulatory effects on larR transcription whereby larR transcript is negatively modulated by 4-HBA while LysRLe, in contrast, exerts positive transcriptional regulation by directly binding to the larR promoter without being affected by 4-HBA in vitro; (iii) that LarR, similar to LysRLe, can bind to the promoter of the HSAF biosynthetic gene operon, leading to positive regulation of HSAF production; and (iv) that LarR and LysRLe cannot interact and instead control HSAF biosynthesis independently. These results outline a previously uncharacterized mechanism by which biosynthesis of the antibiotic HSAF in L. enzymogenes is modulated by the interplay of 4-HBA, a diffusible molecule, and two different TFs.
IMPORTANCE Bacteria use diverse chemical signaling molecules to regulate a wide range of physiological and cellular processes. 4-HBA is an “old” chemical molecule that is produced by diverse bacterial species, but its regulatory function and working mechanism remain largely unknown. We previously found that 4-HBA in L. enzymogenes could serve as a diffusible factor regulating HSAF synthesis via LysRLe. Here, we further identified LarR, an MarR family protein, as a second TF that participates in the 4-HBA-dependent regulation of HSAF biosynthesis. Our results dissected how LarR acts as a protein linker to connect 4-HBA and HSAF synthesis, whereby LarR also has cross talk with LysRLe. Thus, our findings not only provide fundamental insight regarding how a diffusible molecule (4-HBA) adopts two different types of TFs for coordinating HSAF biosynthesis but also show the use of applied microbiology to increase the yield of the antibiotic HSAF by modification of the 4-HBA regulatory pathway in L. enzymogenes.
KEYWORDS: 4-HBA, HSAF, Lysobacter, MarR
INTRODUCTION
The Gram-negative genus Lysobacter comprises a group of ubiquitous environmental bacteria, emerging as a rich resource for discovering new antibiotics (1). Of them, Lysobacter enzymogenes is the best-studied species and serves as an important biocontrol resource that has an efficient antagonistic effect on pathogenic filamentous fungi and oomycetes and plant parasitic nematodes (2–5). The antagonistic effects of this species are partly due to production of a polycyclic tetramate macrolactam (PTM)-type antifungal secondary metabolite, called heat-stable antifungal factor (HSAF), whose structure is remarkably different from structures of fungicides on the market (6, 7). The HSAF pks and nrps genes that code for a hybrid polyketide synthase (PKS) and a nonribosomal peptide synthetase (NRPS) are responsible for HSAF biosynthesis in L. enzymogenes (8, 9). Although HSAF has great potential to be developed as a biopesticide or antifungal drug, the original yield (1.8 μg/ml) of HSAF in L. enzymogenes is relatively low even in HSAF-inducing medium (4, 8). This fact restricts the extensive application of HSAF not only in the control of plant diseases but also in the inhibition of animal pathogens, especially in the case of antibiotic resistance (10, 11). Based on our knowledge, in addition to heterologous expression of the HSAF biosynthetic gene cluster (9), artificial synthesis, and optimized fermentation, understanding the regulation mechanism of HSAF biosynthesis is also greatly beneficial in constructing high-yield HSAF strains that improve the production of HSAF.
In order to reach this goal, we have identified three key transcription factors (TFs) that control HSAF production. These include the LuxR family protein LesR (a negative regulator), the global regulator Clp (a positive regulator), and the TetR family protein LetR (a negative regulator) (12–14). Apart from these regulators, we also found small-molecule metabolites, such as diffusible signal factor (DSF; a type of fatty acid compound) and diffusible factor (DF), that participate in the biosynthesis of HSAF (15). We along with our collaborators further showed that the RpfC/RpfG two-component system and Clp mediate the DSF signaling pathway and that L. enzymogenes LysR (LysRLe) is involved in the DF regulatory cascade (16). The DF was recently identified as 4-hydroxybenzoic acid (4-HBA) in L. enzymogenes, and this molecule is predicted to be produced by a wide range of bacterial species (16). The L. enzymogenes 4-HBA is synthesized by LenB2 (a pteridine-dependent dioxygenase-like protein) using chorismate, the end product of shikimate pathway, as the substrate (16). LysRLe links the 4-HBA cascade to HSAF synthesis because, on one hand, according to our recent work (16), LysRLe could bind to the lafB gene (the originally described HSAF PKS/NRPS gene) promoter (also called the HSAF promoter, abbreviated as pHSAF) and, as a result, directs expression of HSAF biosynthetic genes and HSAF production; on the other hand, LysRLe interacts with 4-HBA directly. Binding with 4-HBA appears to partly promote the binding of LysRLe to pHSAF in vitro. However, at this moment we cannot conclude that binding of 4-HBA affects the binding of LysRLe to pHSAF, which would explain the change in HSAF output due to transcriptional activation (16). Our previous findings raise a great possibility that 4-HBA may be involved in stabilizing an LysRLe-DNA (pHSAF) complex with an unidentified protein in L. enzymogenes (16). Nevertheless, these earlier findings provide a first TF (LysRLe) linking 4-HBA regulation to HSAF biosynthesis in L. enzymogenes.
The objective of this study was to identify new potent TFs within the 4-HBA regulatory pathway that control HSAF levels and further dissect their genetic/biochemical relationship with LysRLe. Here, we show that LarR (Le4806), an MarR family protein, is the second regulator connecting the 4-HBA cascade to HSAF synthesis. First, 4-HBA negatively regulates the transcription of larR; second, LarR positively controls HSAF levels by direct binding to pHSAF, similar to that of LysRLe; third, larR transcription is positively controlled by LysRLe as LysRLe could bind to the larR promoter, but LarR failed to directly bind to the lysRLe promoter. Finally, we show that although LysRLe and LarR both serve as key components of the 4-HBA regulatory pathway, both regulators appear to employ independent mechanisms of modulating HSAF biosynthesis. Therefore, our results reveal that antifungal antibiotic HSAF biosynthesis in L. enzymogenes is modulated by the interplay of two transcription factors (LysRLe and LarR) and a diffusible molecule (4-HBA), presenting a new fundamental mechanism underlying a conserved bacterial chemical molecule (4-HBA) in functional performance. From an applied microbiology point of view, our findings also open a way to improve the yield of the antibiotic HSAF by engineering the components of the 4-HBA regulatory pathway (i.e., LarR) in L. enzymogenes.
RESULTS
LarR is an MarR family transcription factor that is transcriptionally repressed by 4-HBA and positively controls HSAF production.
To discover any new TFs within the 4-HBA regulatory pathway controlling HSAF production, we reanalyzed the published LenB2-based transcriptomic data, according to which LenB2 is the enzyme responsible for 4-HBA production (15, 16). This investigation led to the identification of three TFs (Le4806, Le4969, and Le3904) from the LenB2 regulon. According to their functional domains, these three TFs belong to the MarR (Le4806), TetR (Le4969), and DeoRC (Le3904) family proteins, respectively (Fig. 1A). To understand their roles in HSAF production, each TF coding gene was accordingly deleted in frame (see Fig. S1A in the supplemental material), and HSAF levels were quantified from each generated mutant. The results showed that deletion of le4969 or le3904 from the wild-type OH11 did not sharply influence HSAF yield, whereas deletion of le4806 (designated larR) almost abolished HSAF production (Fig. 1B and S1B). These results revealed that larR may regulate the biosynthesis of HSAF. To confirm this conclusion, an larR expression plasmid (Table 1) was introduced into the larR mutant, which almost restored HSAF production to the level of the wild type (Fig. 1B and S2A). Under similar test conditions, introduction of an empty vector to the larR mutant did not rescue HSAF production. Moreover, mutation of larR did not affect the growth ability of the wild type in the test HSAF-inducing medium (Fig. S2B). Finally, we performed detailed sequence analyses and found that LarR contains all conserved domains or motifs expressed by the well-studied MarR family proteins (Fig. S3), confirming that LarR is an MarR-like protein. Taken together, these results strongly suggest that LarR participated in regulating the biosynthesis of HSAF.
FIG 1.
LarR (Le4806) is one of three transcription factors that belong to the LenB2 regulon and control HSAF production in L. enzymogenes OH11. (A) Bioinformatics analyses of the domain organization of three transcription factors (TFs) that belong to the LenB2 regulon. These three TFs belong to the MarR (Le4806), TetR (Le4969), and DeoRC (Le3904) protein families, and the protein numbers GLE-2208, GLE-2037, and GLE-3130, respectively, correspond to their homologues in L. enzymogenes C3, as indicated. (B) In vivo production of HSAF was modulated by larR in L. enzymogenes OH11. OH11, wild-type strain; ΔlarR, the larR deletion mutant; CPlarR, the complemented strain of ΔlarR containing a plasmid-borne larR; ΔlarR(pBBR), the larR mutant containing an empty vector (pBBR1-MCS5). Data of triplicate experiments are shown. **, P < 0.01. aa, amino acid.
TABLE 1.
Bacterial strains and plasmids used in this study
Strains and plasmids | Descriptiona | Source or reference |
---|---|---|
Lysobacter enzymogenes strains | ||
OH11 | Wild type, Kmr | 5 |
ΔlenB2 strain | lenB2 in-frame deletion mutant, Kmr | 15 |
Δle4969 strain | le4969 in-frame deletion mutant, Kmr | This study |
Δle3904 strain | le3904 in-frame deletion mutant, Kmr | This study |
ΔlarR strain | larR in-frame deletion mutant, Kmr | This study |
ΔlarR (larR) strain | ΔlarR harboring plasmid pBBR-larR, Gmr Kmr | This study |
ΔlarR(pBBR) strain | ΔlarR harboring plasmid pBBR1-MCS5, Gmr Kmr | This study |
ΔlenB2 ΔlarR strain | lenB2 and larR in-frame deletion mutant, Kmr | This study |
ΔlenB2 ΔlarR (lenB2) strain | ΔlenB2 ΔlarR strain harboring plasmid pBBR1-lenB2, Gmr Kmr | This study |
ΔlenB2 ΔlarR (larR) strain | ΔlenB2 ΔlarR strain harboring plasmid pBBR1-larR, Gmr Kmr | This study |
ΔlenB2 ΔlarR(pBBR) strain | ΔlenB2 ΔlarR strain harboring plasmid pBBR1-MCS5, Gmr Kmr | This study |
ΔlarR ΔlysRLe strain | larR and lysRLe in-frame deletion mutant, Kmr | This study |
ΔlarR ΔlysRLe (larR) strain | ΔlarR ΔlysRLe strain harboring plasmid pBBR1-larR, Gmr Kmr | This study |
ΔlarR ΔlysRLe (lysRLe) strain | ΔlarR ΔlysRLe strain harboring plasmid pBBR1-lysRLe, Gmr Kmr | This study |
ΔlarR ΔlysRLe(pBBR) strain | ΔlarR ΔlysRLe strain harboring plasmid pBBR1-MCS5, Gmr Kmr | This study |
Escherichia coli strains | ||
DH5α | λ− ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rK− mK−) supE44 thi-1 gyrA relA1 | 15 |
BL21(DE3) | F− ompT hsdSB(rB− mB−) gal dcm (DE3) | 16 |
XL1-Blue MRF′ Kan | Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F′ proAB lacIqZΔM15 Tn5 (Kmr)] | 28 |
Plasmids | ||
pEX18GM | Suicide vector with a sacB gene, Gmr | 31 |
pEX18-lenB2 | pEX18GM with two flanking fragments of lenB2, Gmr | 15 |
pEX18-larR | pEX18GM with two flanking fragments of larR, Gmr | This study |
pEX18-le4969 | pEX18GM with two flanking fragments of le4969, Gmr | This study |
pEX18-le3904 | pEX18GM with two flanking fragments of le3904, Gmr | This study |
pBBR1-MCS5 | Broad-host-range vector with a Plac promoter | 32 |
pBBR-lenB2 | pBBR1-MCS5 cloned with a 1,553-bp fragment containing intact lenB2 and its predicted promoter | 15 |
pBBR-larR | pBBR1-MCS5 cloned with a 1,223-bp fragment containing intact larR and its predicted promoter | This study |
pBBR-lysRLe | pBBR1-MCS5 cloned with a 1,467-bp fragment containing intact lysRLe and its predicted promoter | This study |
pSS122 | Promoter-probe plasmid containing a promoterless uidA, Gmr | 27 |
p-larR | The promoter region (470 bp) of larR cloned into pSS122, Gmr | This study |
pTRG | The plasmid used for protein expression in bacterial one- or two-hybrid assay, Tetr | 28 |
pTRG-larR | pTRG with the coding region of larR, Tetr | This study |
pTRG-GacS | pTRG with the coding region of gacS, Tetr | 33 |
pBXcmT | The plasmid used for DNA cloning in bacterial one-hybrid assay, Chlor | 28 |
pBXcmT-lafB | pBXcmT with pHSAF (the predicted lafB promoter region), Chlor | 14 |
pBT | The plasmid used for protein expression in bacterial two-hybrid assay, Chlor | 28 |
pBT-lysRLe | pBT with the coding region of lysRLe, Chlor | This study |
pBT- GacS | pBT with the coding region of gacS, Chlor | 33 |
pTRG-lysRLe | pTRG with the coding region of lysRLe, Tetr | This study |
pBXcmT-larR | pBXcmT with pLarR (the predicted larR promoter region), Chlor | This study |
pET30a | Inducible expression vector, C-terminal His tag, Kmr, IPTG inducible | 16 |
pET30a-lysRLe | Plasmid used for protein expression in BL21(DE3), Kmr | 16 |
Kmr, Gmr, Ampr, Tetr, and Chlor are kanamycin, gentamicin, ampicillin, tetracycline, and chloramphenicol resistance markers, respectively.
According to our earlier report (15), larR transcription is negatively controlled by LenB2. To validate this finding, we performed a promoter activity assay. The recombined construct consists of the larR promoter and a promoterless glucuronidase (GUS) gene, uidA. This construct (p-larR) was introduced into the wild-type OH11 and the lenB2 mutant. We found that the larR promoter exhibited significantly higher promoter activity (GUS activity) in the background of the lenB2 deletion than in the OH11 wild-type strain (Fig. 2A), which is in agreement with our earlier finding mentioned above (15). LenB2 could catalyze chorismate to generate 3-HBA and 4-HBA, whereas only 4-HBA is related to the biosynthesis of HSAF (16). Therefore, only 4-HBA at a concentration of 1 μM was added to the culture medium of the ΔlenB2(p-larR) strain because such a low concentration of 4-HBA is sufficient to act as a diffusible factor in restoring the lenB2 mutant to produce wild-type HSAF (16). In accordance with this, applying 4-HBA to the ΔlenB2(p-larR) mutant significantly reduced the larR promoter activity to a level similar to that of the wild-type OH11, while supplementation of 3-HBA in the culture medium of the ΔlenB2(p-larR) mutant had only a minor effect (Fig. 2A), suggesting that 4-HBA plays a key role in suppressing larR transcription. The empty plasmid pSS122 was also introduced into the culture medium of the wild-type OH11 or ΔlenB2 strain to serve as a negative control in the testing of promoter activity. The strains that contained the empty vector displayed almost no GUS activity regardless of the presence or absence of 4-HBA or 3-HBA (Fig. 2A). Moreover, quantitative reverse transcription-PCR (qRT-PCR) assays showed that the molecule 4-HBA repressed larR expression in the background of an lenB2 gene deficiency, but 3-HBA did not perform such a function under similar test conditions (Fig. 2B). In conclusion, these results collectively suggest that LarR is involved in regulating HSAF biosynthesis and that larR transcription is negatively controlled by 4-HBA in L. enzymogenes.
FIG 2.
4-HBA negatively controls the transcription of larR. (A) Supplementation with 4-HBA, but not 3-HBA, at 1 μM had a significant effect on suppression of the activity (GUS activity) of larR in the lenB2 mutant. P-larR represents the larR promoter. pSS122 is an empty vector that was both introduced into the wild-type OH11 and the lenB2 mutant, generating OH11(pSS122) and ΔlenB2(pSS122), respectively. (B) Addition of 4-HBA, but not 3-HBA, at 1 μM remarkably inhibited the transcription of larR in the lenB2 mutant as determined by qRT-PCR. Data of triplicate experiments are shown. **, P < 0.01.
LarR is within the 4-HBA regulatory pathway and directly binds to the HSAF promoter.
The above results suggest that LarR is a downstream component of the 4-HBA regulatory cascade in modulation of HSAF biosynthesis. To provide more supporting evidence, we generated a mutant (ΔlenB2 ΔlarR strain) lacking both larR and lenB2 (Table 1), and its identity was confirmed by RT-PCR (Fig. S4A). The ability of this double mutant to produce HSAF was tested. As expected, deletion of lenB2 and larR almost completely impaired HSAF production (Fig. 3 and S4B). Then, single-gene complementation of the ΔlenB2 ΔlarR double mutant was accomplished by introducing plasmid-borne lenB2 or larR (Fig. S4A). The results showed that individual introduction of larR into the ΔlenB2 ΔlarR double mutant significantly rescued HSAF production deficiency to almost the wild-type level, whereas the single introduction of lenB2 did not yield a similar result (Fig. 3 and S4B). As a control, transformation of an empty vector did not restore the HSAF yield. These data suggest that larR is downstream of lenB2 in vivo in L. enzymogenes. Subsequently, we added 3-HBA and 4-HBA to the culture medium of the double mutant in vitro and tested HSAF production. The results, as shown in Fig. 3 and S4B, were consistent with those of the ΔlenB2 ΔlarR (lenB2) strain, suggesting that in the absence of LarR, addition of 4-HBA could not rescue HSAF production deficiency, providing another piece of evidence to highlight the importance of LarR in the 4-HBA regulatory cascade controlling HSAF production. Taken together, the results reveal that LarR was functionally located in the 4-HBA regulatory pathway and modulated HSAF production.
FIG 3.
LarR is a downstream component of the LenB2 regulatory pathway controlling HSAF production in L. enzymogenes OH11. Single introduction of larR, but not lenB2, rescued the deficiency of the double mutant (ΔlenB2 ΔlarR strain) in producing HSAF. Addition of 3-HBA or 4-HBA to the double mutant had no effect on this function. ΔlenB2 ΔlarR, strain with deletion of both lenB2 and larR; ΔlenB2 ΔlarR (lenB2), complementation of lenB2 in the ΔlenB2 ΔlarR strain; ΔlenB2 ΔlarR (larR), complementation of larR in the ΔlenB2ΔlarR strain; ΔlenB2 ΔlarR(pBBR), the ΔlenB2 ΔlarR mutant containing an empty vector, pBBR1-MCS5. Data of triplicate experiments are shown. **, P < 0.01.
How does LarR control HSAF biosynthesis? To address this question, we tested whether LarR has an ability to bind pHSAF, resulting in directing HSAF gene expression and HSAF production. To test this hypothesis, we used a bacterial one-hybrid reporter system to test the direct binding of LarR to pHSAF. As shown in Fig. 4A, we clearly observed that the transformed Escherichia coli strain that contained both LarR and pHSAF grew very well on selective medium, as did the positive control, whereas the negative control did not successfully grow under similar conditions. This result reveals that direct binding of LarR to pHSAF occurred under the test conditions. To further verify the above finding, an electrophoretic mobility shift assay (EMSA) was carried out. His-tagged LarR protein was purified (Fig. 4B). As shown in Fig. 4C, the concentration-dependent protein-DNA complex formation that is triggered by LarR was evidently detected (from 0.1 to 2 μM) and could be specifically and competitively inhibited by an unlabeled HSAF promoter probe (cold probe) at a 100- or 200-fold excess concentration. To further validate the binding specificity of LarR to pHSAF, we selected the promoter region of le1974 (p1974; 295 bp) as a new probe to test whether it could competitively inhibit LarR-pHSAF complex formation. le1974 encodes a GGDEF domain-containing protein potentially responsible for synthesizing c-di-GMP, an intracellular nucleotide second messenger (17). To the best of our knowledge, p1974 should be unrelated to the binding capacity of LarR to pHSAF. Our results showed that addition of p1974 at different concentrations into the EMSA mixture containing LarR and pHSAF did not inhibit formation of the complex LarR-pHSAF (Fig. S5). In agreement, LarR could not bind to p1974 under the in vitro EMSA conditions (Fig. S5). These discoveries, together with the results of HSAF yield (Fig. 1B), powerfully support the hypothesis that LarR could specifically bind to the HSAF promoter and regulate HSAF biosynthesis.
FIG 4.
LarR directly bound to the HSAF promoter. (A) The direct physical interaction between LarR and the HSAF promoter, pHSAF (the promoter of lafB, the key biosynthetic gene of HSAF) was detected in E. coli. Experiments were performed according to the procedures described in the Materials and Methods section. BOH-CK(+), cotransformant containing pBX-R2031 and pTRG-R3133, used as a positive control; pTRG/pHSAF, cotransformant containing pBXcmT-lafB and the empty pTRG, serving as a negative control; pTLarR/pHSAF, cotransformant possessing both pTRG-larR and pBXcmT-lafB (Table 1). −3AT-Strr, plate without selective medium; +3AT+Strr, plate with selective medium. (B) SDS-PAGE of the His-tagged, purified LarR, as indicated. Lane M, molecular mass marker. (C) LarR bound to the HSAF promoter (pHSAF) in vitro as determined by an EMSA. The free DNA (the labeled pHSAF) and protein-DNA complex are indicated by arrows. The unlabeled probe (cold probe) at a 100- or 200-fold excess to the reaction mixtures can efficiently and competitively inhibit the binding of LarR to the labeled DNA probe (pHSAF).
LysRLe could directly bind to the larR promoter.
The above results provide strong evidence to show that LarR is a second key TF, in addition to LysRLe, within the 4-HBA cascade regulating HSAF synthesis. Thus, it is of great interest to question the relationship between LysRLe and LarR. As both TFs could bind to the HSAF promoter, we first investigated whether there is an interaction between the two factors in the binding of the HSAF promoter. For this purpose, a BacterioMatch II bacterial two-hybrid experiment was performed, as described in detail in Materials and Methods. Our results show that the transformed E. coli strain that contained both the LarR and LysRLe proteins did not grow any more on the selective medium, but the positive control grew well (Fig. S6). These results suggest that LarR and LysRLe may not interact with each other during their binding to the HSAF promoter.
Since 4-HBA affects larR transcription as described above (Fig. 2A), we investigated whether 4-HBA could control larR transcription via LysRLe because LysRLe is the 4-HBA receptor and has a DNA-binding domain (16). To test this hypothesis, we first tested the potential binding of LysR to the larR promoter (pLarR) by employing the bacterial one-hybrid reporter system described above. As shown in Fig. 5A, we clearly observed that the transformed E. coli strain that contained both the LysRLe regulator and pLarR grew very well on the selective medium, as did the positive control; however, the negative control did not successfully grow under similar conditions. This result indicated that direct binding of LysRLe to pLarR occurred under the test conditions.
FIG 5.
LysRLe directly bound the promoter of larR. (A) The direct physical interaction between LysRLe and the larR promoter region was detected in E. coli. BOH-CK(+), cotransformant containing pBX-R2031 and pTRG-R3133, used as a positive control; pTRG/pLarR, cotransformant containing pBXcmT-larR and the empty pTRG, used as a negative control; pTLysRLe/pLarR, cotransformant containing both pTRG-lysRLe and pBXcmT-larR (Table 1). pLarR, the larR promoter described in the text; −3AT-Strr, nonselective medium plate; +3AT+Strr, selective medium plate. (B) LysRLe bound to the larR promoter region in vitro as determined by an EMSA. The arrows indicate the free DNA (the labeled pLarR) and protein-DNA complex. The unlabeled probe (cold probe) at a 10- to 200-fold excess could efficiently and competitively inhibit the binding of LysRLe to the labeled DNA probe (pLarR).
To better verify the above findings, an EMSA was carried out. As shown in Fig. 5B, concentration-dependent protein-DNA (pLarR) complex formation, triggered by LysRLe, was obviously detected (from 0.01 to 0.5 μM) and could be competitively repressed by an unlabeled larR promoter probe (cold probe) at a 100- or 200-fold excess concentration, suggesting that LysRLe could specifically bind to pLarR in vitro. As further supporting evidence, we found that p1974 at different concentrations could not inhibit LysRLe-pLarR complex formation (Fig. S7). Consistent with this, LysRLe failed to bind p1974 under the in vitro EMSA conditions (Fig. S7). Next, given that LysRLe is the receptor of 4-HBA (16), a series of different concentrations of 4-HBA was added to the EMSA system to test whether 4-HBA enhances or represses the binding of LysRLe to pLarR. The results (Fig. S8) showed that 4-HBA at all test concentrations neither enhanced nor repressed the interaction of LysRLe with pLarR; these results matched those of the negative control, 3-HBA. These data imply that LysRLe could bind to pLarR without the influence of 4-HBA or 3-HBA in vitro. It is also important that LarR could not bind to the lysRLe promoter under the in vitro EMSA conditions (Fig. S9). Taken together, our results showed that LysRLe could specifically bind to pLarR, suggesting that LysRLe may control the transcription of larR (see below).
LysRLe and 4-HBA play opposite roles in larR transcription.
To explore whether LysRLe has a regulatory effect on larR transcription, we quantified the relative expression of larR in the lysRLe mutant by qRT-PCR. The results (Fig. 6) showed that, compared to wild-type OH11, the larR expression in the lysRLe mutant was significantly low, suggesting that LysRLe positively regulates larR transcription. This finding is in contrast to the case of 4-HBA, where 4-HBA negatively controls larR transcription. This observation prompted us to determine the coregulatory effect of 4-HBA and LysRLe. We thus generated a double mutant lacking both lenB2 and lysRLe (Table 1). Surprisingly, we found that larR expression in this double mutant was significantly higher than that in the wild-type OH11 (Fig. 6). Adding 4-HBA but not 3-HBA could remarkably suppress larR expression in the background of double mutations (Fig. 6). These results collectively revealed that 4-HBA and LysRLe play opposite roles in larR transcription, with 4-HBA having a bigger effect.
FIG 6.
4-HBA and LysRLe play opposite roles in larR transcription, with 4-HBA having a bigger effect. Mutation of lysRLe significantly impaired larR transcription. Addition of 4-HBA or 3-HBA to the lysRLe mutant (ΔlysRLe strain) did not rescue its deficiency in transcribing larR. Double mutation of lenB2 and lysRLe (ΔlenB2 ΔlysRLe strain) sharply increased larR transcription, while supplementation of 4-HBA but not 3-HBA in this double mutant could significantly restore larR transcription compared to that of the double mutant. Data of triplicate experiments are shown. **, P < 0.01; n.s., not significant.
LysRLe and LarR appear to independently regulate HSAF biosynthesis.
All of the results described above suggest that both LarR and LysRLe are key regulators of the 4-HBA cascade in modulating HSAF biosynthesis, where 4-HBA and LysRLe control the transcription of larR in opposite ways, suggesting that LysRLe and LarR may regulate HSAF production independently. To test such a hypothesis, a double mutant (ΔlarR ΔlysRLe strain) having deletions of both larR and lysRLe was generated (Table 1), followed by testing of its HSAF yield. As shown in Fig. 7, we observed that this double mutant almost lost the ability to produce HSAF; its HSAF yield was lower than that of the larR or lysRLe single mutant. Single introduction of the plasmid-borne larR or lysRLe into this double mutant had no visible effect on rescuing the HSAF production deficiency, suggesting that LysRLe and LarR may independently regulate HSAF production at the genetic level.
FIG 7.
LysRLe and LarR are likely to independently control HSAF production. Double mutation of larR and lysRLe (ΔlarR ΔlysRLe) significantly impaired HSAF production, while single introduction of larR or lysRLe could not rescue the deficiency of the double mutant in producing HSAF. ΔlarR ΔlysRLe (larR), the complementation of larR in the ΔlarR ΔlysRLe strain; ΔlarR ΔlysRLe (lysRLe), the complementation of lysRLe in the ΔlarR ΔlysRLe strain; ΔlarR ΔlysRLe(pBBR), the mutant ΔlarR ΔlysRLe containing an empty vector, pBBR1-MCS5. Data of triplicate experiments are shown. **, P < 0.01; n.s., not significant.
DISCUSSION
4-HBA is a newly identified diffusible factor that regulates antifungal antibiotic HSAF biosynthesis in L. enzymogenes (16). This chemical molecule is further predicted to be widely produced by a diverse range of bacterial species (16, 18), but the functionality and underlying mechanism remain poorly understood. In L. enzymogenes, we previously showed that LysRLe, an LysR family TF, could serve as the 4-HBA receptor mediating the 4-HBA functional performance (16). Here, we have identified LarR, a member of the MarR protein family, as a second TF participating in 4-HBA-dependent HSAF biosynthesis, whereby 4-HBA and LysRLe have opposite regulatory effects on larR transcription, with 4-HBA having a bigger effect. These findings establish a bridge to connect one diffusible molecule (4-HBA) to two different types of TFs (LysRLe and LarR) in control of the same phenotype (HSAF production) in L. enzymogenes. Our results thus show that the biosynthesis of a unique secondary metabolite (HSAF) in an agriculturally important bacterium (L. enzymogenes) is controlled by the interplay of two TFs with 4-HBA, a conserved bacterial chemical molecule, which expands our current understanding of the working mechanism used by 4-HBA in bacteria. Our findings may trigger additional studies in 4-HBA-producing bacteria. The fundamental knowledge generated from the present study is greatly helpful in improving HSAF yield by supplying 4-HBA as a direct fermentation supplement and/or by generating higher-HSAF-producing strains via genetic and metabolic engineering of the regulators within the 4-HBA regulatory pathway.
The MarR family proteins are a large group of TFs widely distributed in bacterial and archaeal domains (19). This group of protein regulators could control bacterial detoxification in response to multiple antibiotics, toxic chemicals, or both (20, 21). Here, we identify LarR, an MarR-like protein that regulates the biosynthesis of HSAF, an antifungal secondary metabolite, via a direct binding mechanism to the HSAF promoter. This finding associates an MarR-like protein with the area of natural product (HSAF) biosynthesis, expanding the role of MarR family proteins in bacteria. As documented previously, MarR-like proteins prefer to form homodimers to bind gene promoter regions via their winged helix-turn-helix (wHTH)-type DNA binding domains, leading to control of expression of the respective genes (22–25). The protein-DNA interactions could be affected by specific phenolic compounds/ligands, such as salicylate, ethidium, and benzoate (22, 26). Earlier reports, along with our finding that LarR is within the 4-HBA regulatory pathway and could control HSAF production by directly binding to the HSAF promoter, raise a possibility that 4-HBA, a phenolic compound, may serve as the ligand of LarR. However, our results did not support this idea because the microscale thermophoresis (MST) data show no binding of LarR to 4-HBA (see Fig. S10 in the supplemental material). We further found that several 4-HBA structural analogs, including 3-HBA (3-hydroxybenzoic acid), 2-HBA (2-hydroxybenzoic acid), 3,4-HBA (3,4-hydroxybenzoic acid), 3,5-HBA (3,5-hydroxybenzoic acid), and 2,5-HBA (2,5-hydroxybenzoic acid) all failed to interact with LarR (Fig. S10). These findings collectively suggest that an unidentified phenolic ligand or other types of ligand may interact with LarR in L. enzymogenes. Thus, searching additional ligands of LarR will be the focus of our future study, which will facilitate our deep understanding of the underlying mechanism involved in the regulation of HSAF biosynthesis by LarR.
A notable finding of the present study was that LysRLe, the 4-HBA receptor, positively modulates larR transcription by directly binding to its promoter, establishing a genetic bridge to connect these two TFs that are both within the 4-HBA regulatory pathway. However, the binding of LysRLe to the larR promoter (pLarR) was not affected by 4-HBA in vitro (Fig. S8) although LysRLe binds 4-HBA directly (16). The mechanism underlying such a phenomenon is unclear at this time, but it is possible that under the in vivo conditions, the LysRLe-pLarR complex may be affected by 4-HBA in combination with an unidentified protein in L. enzymogenes. Testing such a possibility is in progress in our laboratory. Although LysRLe established cross talk with larR by binding to its promoter (Fig. 5), LarR did not seem to perform similarly with lysRLe as LarR failed to bind the lysRLe promoter (Fig. S9). Furthermore, LarR is also not likely to interact with LysRLe, as determined by a bacterial two-hybrid assay (Fig. S6). Based on our present understanding, it is thus likely that LarR did not establish cross talk with LysRLe by binding to the lysRLe promoter or interacting with LysRLe. Another interesting observation made in the present study was that LysRLe and 4-HBA play opposite roles in larR transcription. LysRLe promoted the transcription of larR by directly binding to its promoter (Fig. 5 and 6), while 4-HBA suppressed the transcription of larR (Fig. 2). The repression of larR transcription by 4-HBA is likely to be independent of LysRLe as addition of 4-HBA could significantly decrease larR transcription in the background of the lenB2 and lysRLe double mutation in the absence of LysRLe (Fig. 6). These findings suggest that an unknown factor, probably independent of LysRLe, may mediate inhibition of larR transcription by 4-HBA in L. enzymogenes. Thus, it is possible that 4-HBA may utilize two independent pathways to control HSAF production in L. enzymogenes. One is mediated by LysRLe, whereby 4-HBA directly interacts with LysRLe and appears to partly enhance LysRLe binding to pHSAF in vitro, leading to direct HSAF production (16). The other is LarR dependent. In this case, 4-HBA is likely to employ unidentified factor(s) (i.e., 4-HBA binding protein), probably independent of LysRLe, to suppress larR transcription. To support this idea, our genetic data further show that regulation by LysRLe and LarR of HSAF production was independent at a genetic level (Fig. 7). However, at this time, it is unclear whether the two regulators (LysRLe and LarR) compete with each other in their binding to pHSAF. Addressing this and related issues, i.e., mapping the binding sites of LysRLe and LarR in pHSAF, is absolutely necessary for future study. It is also of great interest to understand why 4-HBA needs to adopt two different types of TFs (LysRLe and LarR) to coordinate HSAF biosynthesis. We do not know the exact answer, but it is likely that perhaps the two TFs play regulatory roles at different times and/or cell localizations as well as under different conditional stimulus responses. Such hypothesized molecular strategies may efficiently enable L. enzymogenes to acquire flexibilities or adaptabilities in determining when and how to generate HSAF via the 4-HBA regulatory network.
In summary, we expanded the proposed model of 4-HBA in regulating HSAF biosynthesis (Fig. 8). In this model, LenB2 uses chorismate, the end product of shikimate pathway, to produce 4-HBA (16). This molecule further employed two different types of TFs to mediate the regulation of 4-HBA in the control of HSAF production. One TF is LysRLe, which could bind the HSAF promoter and thereby direct HSAF biosynthetic gene expression and HSAF production (16). In this process, 4-HBA interacts with LysRLe to partly enhance the binding of LysRLe to the HSAF promoter (16). The other TF is LarR, which can also bind to the HSAF promoter, but LarR did not bind 4-HBA. 4-HBA negatively controls larR transcription, probably via an uncharacterized factor, while LysR has a positive effect on larR transcription by directly binding to its promoter region. Our results thus suggest that the interplay of 4-HBA with two different TFs plays a key role in regulating HSAF biosynthesis in L. enzymogenes, which has not been reported in other 4-HBA-producing bacteria.
FIG 8.
An expanding model for LarR-mediated regulatory pathway of 4-HBA in modulating HSAF biosynthesis in L. enzymogenes. LenB2 catalyzes the end product of the shikimate pathway, chorismate, to produce 4-HBA. 4-HBA further employs two different types of TFs to mediate the regulation of 4-HBA in controlling HSAF production. One TF is the reported LysRLe, which could bind the HSAF promoter, thus directing HSAF biosynthetic gene (i.e., lafB) expression and HSAF production (16). In this process, 4-HBA may partly enhance the binding of LysRLe to the HSAF promoter (16). The other is LarR, presented in this study, which can also bind to the HSAF promoter; however, LarR did not bind 4-HBA. 4-HBA negatively controls larR transcription, probably via an uncharacterized factor (indicated by a question mark), while LysR has a positive effect on larR transcription by directly binding to its promoter region. LarR failed to bind the promoter of lysRLe. Thus, the interplay of 4-HBA with two TFs within its regulatory cascade plays a key role in regulating HSAF biosynthesis in L. enzymogenes, which has not been discovered in other 4-HBA-producing bacteria. TCA, tricarboxylic acid.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions.
The bacterial strains and plasmids that were used in this study are listed in Table 1. Escherichia coli strains DH5α, XL1-Blue MRF′ Kan, and BL21(DE3) were used for plasmid construction, bacterial one- and two-hybrid assays, and protein expression, respectively. All E. coli strains that were used for plasmid construction were usually grown in Luria broth (LB) at 37°C, supplemented with kanamycin (Km; 25 μg/ml) and gentamicin (Gm; 25 μg/ml) or 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal; 100 μg/ml) as needed for solid and liquid media. Lysobacter enzymogenes strains were grown in LB medium or 1/10 tryptic soy broth (TSB) at 28°C. When required, antibiotics were added to the medium to the following final concentrations: kanamycin, 100 μg/ml; Gm, 150 μg/ml.
Promoter activity assay.
The promoter region of lafB, also called the HSAF promoter (pHSAF), was amplified by PCR and cloned into the promoter-probe plasmid pSS122 (Table 1), which carries a promoterless uidA gene that encodes GUS activity (27). This combined construct was transformed into the wild-type OH11 and its derivatives by electroporation. Next, overnight cultures of strains containing constructed reporter plasmids in the HSAF-inducing medium (10% TSB) were centrifuged at 12,000 rpm at 4°C for 3 min, and the cells were collected. Then, cells were resuspended in 600 μl of GUS buffer (50 mM sodium phosphate, pH 7.0, 1 mM EDTA, and 14.3 mM β-mercaptoethanol), and 23 μl of 3% Triton X-100 and sodium lauroyl sarcosinate was added. The mixture was incubated at 30°C for 10 min. Last, 100 μl of 25 mM p-nitrophenyl-β-d-glucuronic acid (PNPG) (Sigma, USA) was added. Time for all test sample reactions in this assay is less than 10 min, but the precise time for each sample varied. During the assays, when a yellow pigment developed for each sample, 280 μl of Na2CO3 solution (1 M) was added to stop the reaction, and the respective reaction time for each sample was immediately recorded in seconds. The promoter activity was calculated as described previously (27). The biological experiments were performed in triplicate, and each biological replicate was assayed three times to reduce technical error.
Bacterial one-hybrid assay.
The bacterial one-hybrid reporter system was shown to efficiently test physical interactions between the transcription factors and the promoter of target genes (28, 29), as exemplified by the interaction between LarR and its target DNA (pHSAF) in the present study. As described previously, the bacterial one-hybrid reporter system consisted of three modules. The plasmids pBXcmT and pTRG were separately used for cloning the bait DNA and expressing a target protein. The E. coli XL1-Blue MRF′ Kan strain (Table 1) is the host strain used to propagate the recombined pBXcmT and pTRG vectors (28, 29). In the present study, the HSAF promoter region (491 bp) of L. enzymogenes OH11 was cloned into pBXcmT, generating the recombinant vector pBXcmT-lafB (Table 1); in addition, the coding region of larR (717 bp) was cloned into pTRG, creating the final construct pTRG-larR (Table 1). The vectors pBXcmT-lafB and pTRG-larR were cotransformed into the XL1-Blue MRF′ Kan strain. If direct physical binding occurred between larR and the HSAF promoter, the positively transformed E. coli strain that contained both pBXcmT-lafB and pTRG-larR was expected to grow well on the selective medium, which is a minimal medium (M9)-based medium that contains 5 mM 3-amino-1,2,4-triazole (3-AT), 8 μg/ml streptomycin (Str), 12.5 μg/ml tetracycline, 34 μg/ml chloramphenicol, and 30 μg/ml kanamycin, as described previously (28, 29). Moreover, a cotransformant containing the vectors pBX-R2031/pTRG-R3133 served as a positive control (28), while the cotransformant containing the empty pTRG and pBXcmT-lafB plasmids was used as a negative control in the present study. All of these cotransformants were spotted onto selective medium and grown at 28°C for 3 or 4 days, at which point they were photographed.
Genetic methods.
A double-crossover homologous recombination strategy was used to generate an in-frame deletion of the gene of interest (GOI) in L. enzymogenes, as described previously (30). In brief, two flanking regions of the GOI were generated by PCR amplification using various corresponding primer pairs (Table 2) and cloned into the respective sites of the suicide vector pEX18Gm (Table 1) (31). The final constructs were transformed into wild-type OH11 or its derivatives by electroporation. Next, Lysobacter transformants on the LB plates were selected by adding Km (100 μg/ml) and Gm (150 μg/ml) in the absence of sucrose. Positive colonies were further cultivated on LB plates that contained 10% (wt/vol) sucrose and Km (100 μg/ml) to select for the correct construct that was generated by a second crossover event. The final mutants were confirmed by PCR and sequencing (see Fig. S1A in the supplemental material).
TABLE 2.
Primers used in this study
Primer | Sequence (restriction enzyme)a | Purpose |
---|---|---|
Le3904-1F | CCCGGTACCGCGGGCGTGCGGGCGAGGGC (KpnI) | To amplify a 201-bp upstream homologuous arm of le3904 |
Le3904-1R | CCCTCTAGAAGGCGGTGGCGTTGCTGCGG (XbaI) | |
Le3904-2F | CCCTCTAGAACTTCCTCGGCGTGTGCGGC (XbaI) | To amplify a 634-bp downstream homologuous arm of le3904 |
Le3904-2R | CCCAAGCTTGGCGATGAAGAAGGCGATGC (HindIII) | |
Le4969-1F | CCCGGTACCCGGGCTTGCGTGGAGTGAGG (KpnI) | To amplify a 347-bp upstream homologuous arm of le4969 |
Le4969-1R | CCCTCTAGATGTCGCCCCCCTCGCCCGCT (XbaI) | |
Le4969-2F | CCCTCTAGACGGGGGCGGCGGCGAGGATG (XbaI) | To amplify a 544-bp downstream homologuous arm of le4969 |
Le4969-2R | CCCAAGCTTGAGGACCGCCAGATTCACCG (HindIII) | |
Le4806-1F | CCCGGTACCAAGGGCGGGCGTGGGGCGGG (KpnI) | To amplify a 220-bp upstream homologuousarm of le4806 (larR) |
Le4806-1R | CCCTCTAGAACGAAGCGGGCGAGGGCGAT (XbaI) | |
Le4806-2F | CCCTCTAGACGGACAGGAACAGCAGGGCG (XbaI) | To amplify a 399-bp downstream homologue arm of le4806 (larR) |
Le4806-2R | CCCAAGCTTACGGACGGGAGGTGGAGGAT (HindIII) | |
Le4806-cF | CGGGGTACCAGTTCGATCAGCCCGTCCC (KpnI) | To amplify a 1223-bp DNA fragment containing intact larR and its promoter |
Le4806-cR | CCCAAGCTTTCAGGGCGAGCGCGCGCCGG (HindIII) | |
Le4806-F | CGCCATATGGCCATGTCCCTCAGCCCGCT (NdeI) | To express and purify LarR in E. coli BL21 |
Le4806-R | CCCAAGCTTGGGCGAGCGCGCGCCGGGCG (HindIII) | |
RT-larR-F | TCATCTCGTCGATCCAGCTG | To amplify a 232-bp DNA fragment to verify larR transcription |
RT-larR-R | GACCACTTCGAGACCTACAAG | |
RT-lenb2-F | CAGTTGGAAGAAACCCTGGC | To amplify a 193-bp DNA fragment to verify lenB2 transcription |
RT-lenb2-R | CATGCACCAGGATCCGCG | |
pTLarR-F | CGGGATCCGCCATGTCCCTCAGCCCGCT (BamHI) | To amplify a 717-bp fragment containing the coding region of larR |
pTLarR-R | CCGCTCGAGGGGCGAGCGCGCGCCGGGCG (XhoI) | |
pTLysRLe-F | CGGGATCCGCTCACGATCTCAACGACAC (BamHI) | To amplify a 1,167-bp fragment containing the coding region of lysRLe |
pTLysRLe-R | CCGCTCGAGCTTATCGTCGTCATCCTTGT (XhoI) | |
p-larR-F | CGGAATTCACCGTAGCCGGTCAATAGGTT (EcoRI) | To amplify a 470-bp fragment containing the larR promoter region |
p-larR-R | GCTCTAGAACCGTAGCCGGTCAATAGGTT (XbaI) | |
pBT-LysRLe-F | TTGCGGCCGCAATGGCTCACGATCTCAACGA (NotI) | To amplify a 1,167-bp fragment containing the coding region of lysRLe |
pBT-LysRLe-R | CCGCTCGAGTTACGCCAACGCCGCATC (XhoI) | |
16S-F | ACGGTCGCAAGACTGAAACT | qRT-PCR (an internal control) |
16S-R | AAGGCACCAATCCATCTCTG | |
q-larR-F | CCTGCTGTTCCTGTCCGA | qRT-PCR |
q-larR-R | CCTTGTAGGTCTCGAAGTGGT | |
p1974-F 1 | TGGTGCTGGGCATCGTCG | To amplify a 295-bp DNA fragment containing the le1974 promoter region |
p1974-R | GTCCCGGCCCGCTCCTGCCT |
Restriction sites are underlined.
For complementation, a plasmid-borne method was utilized to generate the complemented strains, as described previously (12, 15). In brief, the DNA fragment that contained the full-length GOI and its predicted promoter region was amplified by PCR with different conjugated primer pairs (Table 2) and cloned into the broad-host-range vector pBBR1-MCS5 (Table 1) (32). The final construct was transformed into competent cells of the GOI mutant by electroporation to generate the corresponding complemented strains; the identity of these strains was confirmed by PCR with the primer pairs that are shown in Table 2.
HSAF extraction and quantification.
Extraction and quantification of the antifungal factor HSAF from various Lysobacter strains by high-performance liquid chromatography (HPLC) (Agilent 1260; USA) were performed as described previously (7, 8, 15). HSAF was extracted from 25-ml L. enzymogenes cultures that were grown in 1/10 TSB for 48 h at 28°C with shaking at 200 rpm. HSAF was detected using HPLC and quantified per unit of optical density at 600 nm (OD600) as described previously (7, 13, 15). Three biological replicates were used, and each was analyzed in three technical replicates.
RT-PCR and q-RT PCR.
Reverse transcription-PCR (RT-PCR) was performed as described previously (12, 15, 16). Briefly, the wild-type OH11 L. enzymogenes strain and its derivatives were cultivated in 1/10 TSB until the OD600 reached 1.0. The cells of each strain were collected by centrifugation (13,000 rpm) at 4°C for 1 min. Total RNA from these cells was extracted using a bacterial RNA kit (catalog no. R6950-01; Omega, China) according to the manufacturer's instructions. To remove genomic DNA, the eluted RNA samples were treated with RNase inhibitors and DNase I (catalog no. E1091; Omega, China). RNA integrity was examined by electrophoresis using 1.2% agarose gels. Then, 2 μg of each RNA sample was chosen for cDNA synthesis using a PrimeScript RT reagent kit with genomic DNA (gDNA) eraser (catalog no. RR047A; TaKaRa, Japan). The subsequent semiquantitative RT-PCR and quantitative RT-PCR (qRT-PCR) assays were performed to amplify the 16S rRNA gene and the GOI with the primer pairs listed in Table 2; the 16S rRNA gene was used in this study as an internal control as described previously (12, 15).
Protein expression and purification.
Expression and purification of the target protein were performed as described previously (14, 16). In brief, larR was amplified by PCR with the primer pairs listed in Table 2. After enzymatic digestion (NdeI/HindIII), this gene was cloned into a pET-30a vector for protein expression in E. coli strain BL21(DE3) (Table 1). The resultant strain was cultivated in LB broth (containing Km at 30 μg/ml) overnight at 37°C. Then, a total of 2 ml of overnight culture was transferred into 300 ml of fresh LB medium that contained 30 μg/ml Km and was then grown at 37°C with shaking at 200 rpm until an OD600 of 0.6 was reached. Subsequently, isopropyl β-d-1-thiogalactopyranoside (IPTG; Sigma) was added to the culture to a final concentration of 1 mM, and the culture was allowed to grow at 18°C for 12 h. Then, the cells were collected by centrifugation (13,000 rpm) at 4°C and resuspended in 25 ml of protein extract buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 1 mM EDTA) that was supplemented with the protease inhibitor phenylmethylsulfonyl fluoride ([PMSF] 10 mM). The cells were briefly lysed by sonication with a Sonifier 250 (Branson Digital Sonifier, Branson, USA), and the cell lysate was centrifuged at 13,000 rpm at 4°C for 30 min. Soluble protein fractions were collected and mixed with preequilibrated Ni2+ resin (GE Healthcare, USA) for 1 h at 4°C; the resin was then placed in a column and extensively washed with binding buffer (50 mM Na3PO4, 30 mM NaCl, and 10 mM imidazole). The desired protein was finally eluted in 50 mM Na3PO4, 30 mM NaCl, and 250 mM imidazole. Protein purity was assessed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and another purification step in which an Amicon Ultra filter unit (Millipore, USA) was used to remove imidazole as well as to exchange the storage buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.5 mM EDTA and 5% glycerol). Finally, the protein concentration was determined using a bicinchoninic acid (BCA) protein assay kit (Sangon Biotech, China).
EMSA.
An electrophoretic mobility shift assay (EMSA) was carried out as follows. Briefly, a biotin-labeled fragment that contained the HSAF promoter region was amplified by PCR using 5′ biotin-labeled primers (Table 2). The biotin-labeled target DNA and protein extract were incubated for 20 min at room temperature according to the protocols of a LightShift Chemiluminescent EMSA kit (Thermo Scientific, USA). Then, the reaction products were loaded onto a polyacrylamide gel, electrophoresed, transferred to a nylon membrane, and cross-linked. Finally, the biotinylated DNA fragments were treated with a chemiluminescent nucleic acid detection module and detected using a VersaDoc imaging system (Bio-Rad, USA).
Bacterial two-hybrid assay.
A BacterioMatch II two-hybrid system was used to determine the potential interaction of two proteins. In detail, the encoding region for each target protein was cloned into pBT (containing a chloramphenicol resistance gene) and pTGR (containing a tetracycline resistance gene). Then, the two constructions were cotransformed into the E. coli reporter strain XL1-Blue MRF′ Kan, which is kanamycin resistant. If the bait protein interacts with the target protein, the transcription of the HIS3 reporter gene will be activated, producing imidazoleglycerol-phosphate dehydratase. As a result, the cotransformed strain could grow in the presence of the compound 3-amino-1,2,4-triazole (3-AT), which is a competitive inhibitor of the product of the HIS3 gene. A second reporter gene, aadA, encoding a protein that confers streptomycin (Str) resistance, provides an additional mechanism to validate the protein-protein interaction. In this experiment, the cotransformed cells were spotted on the selective medium, which is a minimal medium (M9)-based medium containing 5 mM 3-AT, 12.5 μg/ml Str, 12.5 μg/ml tetracycline, 34 μg/ml chloramphenicol, and 30 μg/ml kanamycin. Furthermore, the vectors, pBT-GacS and pTRG-GacS were constructed in this work (Table 1), and the cotransformant containing both vectors served as a positive control because the cytoplasmic domain of GacS from Pseudomonas aeruginosa is known to interact with itself (33). The cotransformant containing the empty pTRG and pBT vectors was used as a negative control in this study. All cotransformants were spotted onto the selective medium and grown at 28°C for 3 to 4 days and then photographed. LB agar is a nonselective medium containing 12.5 μg/ml tetracycline, 34 μg/ml chloramphenicol, and 30 μg/ml kanamycin. The purpose of this medium is to ensure that both vectors are successfully transformed into the host E. coli XL1-Blue MRF′ Kan.
Microscale thermophoresis assay.
The binding affinity between LarR and 4-HBA as well as its analogue was determined by microscale thermophoresis (MST) using a Monolith NT.115 machine (NanoTemper Technologies, Germany) (34). Briefly, purified LarR was fluorescently labeled with NT-647-NHS dye (available from NanoTemper Technologies GmbH, Germany) via amine conjugation. A constant concentration (500 μM) of the labeled target protein (LarR) in standard MST buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM MgCl2, and 0.05% Tween 20) was titrated against increasing concentrations of 4-HBA and its analogue, which were dissolved in methanol and diluted to working concentrations with MST buffer. MST premium-coated capillaries (Monolith NT.115 MO-K005; Germany) were used to load the samples into the MST instrument at 25°C using 40% MST power and 20% LED power. Laser on and off times were set at 30 and 5 s, respectively. All experiments were performed in triplicate. Data analyses were performed using NanoTemper Analysis software, version 1.2.101 (NanoTemper Technologies, Germany).
Data analysis.
All analyses were conducted using SPSS, version 14.0 (SPSS, Inc., Chicago, IL, USA). The hypothesis test of percentages (t test, P = 0.05 or 0.01) was used to determine significant differences in HSAF production, promoter activity, and gene expression levels of the test L. enzymogenes strains.
Accession number(s).
The sequence data of the present study have been submitted to the NCBI GenBank under accession numbers MG266897 (Le4806/LarR), MG266898 (Le4969), MG266895 (Le3904), MG266896 (Le1974), MG266894 (Le1703/LysRLe), and MG266893 (Le1457/LenB2).
Supplementary Material
ACKNOWLEDGMENTS
We thank Benard Omondi Odhiambo for critically reviewing and revising the manuscript.
This study was supported by the National Natural Science Foundation of China (31371981 to G.Q.), National Basic Research (973) program of China (2015CB150600 to G.Q.), National Key Research and Development Program (2017YFD0201100 to G.Q. and F.L.), the Jiangsu Provincial Key Technology Support Program (BE2015354 to F.L.), the 948 Project of the Ministry of Agriculture (2014-Z24 to F.L.), the National Pear Industry Technology System (CARS-28-16 to F.L.), the Special Fund for Agro-Scientific Research in the Public Interest (no. 201303015 to G.Q. and F.L.), and the Innovation Team Program for Jiangsu Universities (2017).
F.L., G.Q., and Z.Q.F. conceived the project and designed experiments. Z.S and S.H carried out experiments. Z.S., S.H., F.L., G.Q., and Z.Q.F. analyzed data. Z.S. and G.Q. wrote the manuscript draft. F.L. and Z.Q.F. revised the manuscript.
Footnotes
Supplemental material for this article may be found at https://doi.org/10.1128/AEM.01754-17.
REFERENCES
- 1.Christensen P, Cook F. 1978. Lysobacter, a new genus of nonfruiting, gliding bacteria with a high base ratio. Int J Syst Evol Microbiol 28:367–393. [Google Scholar]
- 2.Palumbo JD, Sullivan RF, Kobayashi DY. 2003. Molecular characterization and expression in Escherichia coli of three β-1,3-glucanase genes from Lysobacter enzymogenes strain N4-7. J Bacteriol 185:4362–4370. doi: 10.1128/JB.185.15.4362-4370.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Chen J, Moore W, Yuen G, Kobayashi D, Caswell-Chen E. 2006. Influence of Lysobacter enzymogenes strain C3 on nematodes. J Nematol 38:233. [PMC free article] [PubMed] [Google Scholar]
- 4.Li S, Du L, Yuen G, Harris SD. 2006. Distinct ceramide synthases regulate polarized growth in the filamentous fungus Aspergillus nidulans. Mol Biol Cell 17:1218–1227. doi: 10.1091/mbc.E05-06-0533.. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Qian GL, Hu BS, Jiang YH, Liu FQ. 2009. Identification and characterization of Lysobacter enzymogenes as a biological control agent against some fungal pathogens. Agric Sci China 8:68–75. doi: 10.1016/S1671-2927(09)60010-9. [DOI] [Google Scholar]
- 6.Graupner P, Thornburgh S, Mathieson J, Chapin E, Kemmitt G, Brown J, Snipes C. 1997. Dihydromaltophilin; a novel fungicidal tetramic acid containing metabolite from Streptomyces sp. J Antibiot (Tokyo) 50:1014–1019. doi: 10.7164/antibiotics.50.1014. [DOI] [PubMed] [Google Scholar]
- 7.Yu F, Zaleta-Rivera K, Zhu X, Huffman J, Millet JC, Harris SD, Yuen G, Li XC, Du L. 2007. Structure and biosynthesis of heat-stable antifungal factor (HSAF), a broad-spectrum antimycotic with a novel mode of action. Antimicrob Agents Chemother 51:64–72. doi: 10.1128/AAC.00931-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Lou L, Qian G, Xie Y, Hang J, Chen H, Zaleta-Rivera K, Li Y, Shen Y, Dussault P, Liu F. 2011. Biosynthesis of HSAF, a tetramic acid-containing macrolactam from Lysobacter enzymogenes. J Am Chem Soc 133:643–645. doi: 10.1021/ja105732c. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Li Y, Chen H, Ding Y, Xie Y, Wang H, Cerny RL, Shen Y, Du L. 2014. Iterative assembly of two separate polyketide chains by the same single-module bacterial polyketide synthase in the biosynthesis of HSAF. Angew Chem Int Ed Engl 53:7524–7530. doi: 10.1002/anie.201403500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Walsh C. 2003. Antibiotics: actions, origins, resistance. ASM Press, Washington, DC. [Google Scholar]
- 11.Xie Y, Wright S, Shen Y, Du L. 2012. Bioactive natural products from Lysobacter. Nat Prod Rep 29:1277–1287. doi: 10.1039/c2np20064c. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Qian G, Xu F, Venturi V, Du L, Liu F. 2014. Roles of a solo LuxR in the biological control agent Lysobacter enzymogenes strain OH11. Phytopathology 104:224–231. doi: 10.1094/PHYTO-07-13-0188-R. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wang Y, Zhao Y, Zhang J, Zhao Y, Shen Y, Su Z, Xu G, Du L, Huffman JM, Venturi V. 2014. Transcriptomic analysis reveals new regulatory roles of Clp signaling in secondary metabolite biosynthesis and surface motility in Lysobacter enzymogenes OH11. Appl Microbiol Biotechnol 98:9009–9020. doi: 10.1007/s00253-014-6072-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wang P, Chen H, Qian G, Liu F. 2017. LetR is a TetR family transcription factor from Lysobacter controlling antifungal antibiotic biosynthesis. Appl Microbiol Biotechnol 101:3273–3282. doi: 10.1007/s00253-017-8117-8. [DOI] [PubMed] [Google Scholar]
- 15.Qian G, Wang Y, Liu Y, Xu F, He Y-W, Du L, Venturi V, Fan J, Hu B, Liu F. 2013. Lysobacter enzymogenes uses two distinct cell-cell signaling systems for differential regulation of secondary-metabolite biosynthesis and colony morphology. Appl Environ Microbiol 79:6604–6616. doi: 10.1128/AEM.01841-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Su Z, Chen H, Wang P, Tombosa S, Du L, Han Y, Shen Y, Qian G, Liu F. 2017. 4-Hydroxybenzoic acid is a diffusible factor that connects metabolic shikimate pathway to the biosynthesis of a unique antifungal metabolite in Lysobacter enzymogenes. Mol Microbiol 104:163–178. doi: 10.1111/mmi.13619. [DOI] [PubMed] [Google Scholar]
- 17.Ryjenkov DA, Tarutina M, Moskvin OV, Gomelsky M. 2005. Cyclic diguanylate is a ubiquitous signaling molecule in bacteria: insights into biochemistry of the GGDEF protein domain. J Bacteriol 187:1792–1798. doi: 10.1128/JB.187.5.1792-1798.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zhou L, Huang T-W, Wang J-Y, Sun S, Chen G, Poplawsky A, He Y-W. 2013. The rice bacterial pathogen Xanthomonas oryzae pv. oryzae produces 3-hydroxybenzoic acid and 4-hydroxybenzoic acid via XanB2 for use in xanthomonadin, ubiquinone, and exopolysaccharide biosynthesis. Mol Plant Microbe Interact 26:1239–1248. doi: 10.1094/MPMI-04-13-0112-R. [DOI] [PubMed] [Google Scholar]
- 19.Perez-Rueda E, Collado-Vides J. 2001. Common history at the origin of the position-function correlation in transcriptional regulators in archaea and bacteria. J Mol Evol 53:172–179. doi: 10.1007/s002390010207. [DOI] [PubMed] [Google Scholar]
- 20.Cohen SP, Levy SB, Foulds J, Rosner JL. 1993. Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. J Bacteriol 175:7856–7862. doi: 10.1128/jb.175.24.7856-7862.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Alekshun MN, Levy SB. 1999. The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol 7:410–413. doi: 10.1016/S0966-842X(99)01589-9. [DOI] [PubMed] [Google Scholar]
- 22.Kumarevel T, Tanaka T, Nishio M, Gopinath SC, Takio K, Shinkai A, Kumar PK, Yokoyama S. 2008. Crystal structure of the MarR family regulatory protein, ST1710, from Sulfolobus tokodaii strain 7. J Struct Biol 161:9–17. doi: 10.1016/j.jsb.2007.08.017. [DOI] [PubMed] [Google Scholar]
- 23.Alekshun MN, Levy SB, Mealy TR, Seaton BA, Head JF. 2001. The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 Å resolution. Nat Struct Biol 8:710–714. doi: 10.1038/90429. [DOI] [PubMed] [Google Scholar]
- 24.Hong M, Fuangthong M, Helmann JD, Brennan RG. 2005. Structure of an OhrR-ohrA operator complex reveals the DNA binding mechanism of the MarR family. Mol Cell 20:131–141. doi: 10.1016/j.molcel.2005.09.013. [DOI] [PubMed] [Google Scholar]
- 25.Wu R-y, Zhang R-g, Zagnitko O, Dementieva I, Maltzev N, Watson JD, Laskowski R, Gornicki P, Joachimiak A. 2003. Crystal structure of Enterococcus faecalis SlyA-like transcriptional factor. J Biol Chem 278:20240–20244. doi: 10.1074/jbc.M300292200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Alekshun MN, Levy SB. 1999. Alteration of the repressor activity of MarR, the negative regulator of the Escherichia coli marRAB locus, by multiple chemicals in vitro. J Bacteriol 181:4669–4672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ferluga S, Venturi V. 2009. OryR is a LuxR-family protein involved in interkingdom signaling between pathogenic Xanthomonas oryzae pv. oryzae and rice. J Bacteriol 191:890–897. doi: 10.1128/JB.01507-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.18. Guo M, Feng H, Zhang J, Wang W, Wang Y, Li Y, Gao C, Chen H, Feng Y, He Z-G. 2009. Dissecting transcription regulatory pathways through a new bacterial one-hybrid reporter system. Genome Res 19:1301–1308. doi: 10.1101/gr.086595.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Xu H, Chen H, Shen Y, Du L, Chou S-H, Liu H, Qian G, Liu F. 2016. Direct regulation of extracellular chitinase production by the transcription factor LeClp in Lysobacter enzymogenes OH11. Phytopathology 106:971–977. doi: 10.1094/PHYTO-01-16-0001-R. [DOI] [PubMed] [Google Scholar]
- 30.Qian G, Wang Y, Qian D, Fan J, Hu B, Liu F. 2012. Selection of available suicide vectors for gene mutagenesis using chiA (a chitinase encoding gene) as a new reporter and primary functional analysis of chiA in Lysobacter enzymogenes strain OH11. World J Microbiol Biotechnol 28:549–557. doi: 10.1007/s11274-011-0846-8. [DOI] [PubMed] [Google Scholar]
- 31.Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. 1998. A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally located DNA sequences: application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212:77–86. doi: 10.1016/S0378-1119(98)00130-9. [DOI] [PubMed] [Google Scholar]
- 32.Kovach ME, Elzer PH, Hill DS, Robertson GT, Farris MA, Roop RM, Peterson KM. 1995. Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes. Gene 166:175–176. doi: 10.1016/0378-1119(95)00584-1. [DOI] [PubMed] [Google Scholar]
- 33.Goodman AL, Merighi M, Hyodo M, Ventre I, Filloux A, Lory S. 2009. Direct interaction between sensor kinase proteins mediates acute and chronic disease phenotypes in a bacterial pathogen. Genes Dev 23:249–259. doi: 10.1101/gad.1739009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. 2010. Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun 1:100. doi: 10.1038/ncomms1093. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.